ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,903Medicare Part D Prescriptions Filled, Including Refills

Rank: 229 out of 2680

$861K Total Retail Price of All Prescriptions

Rank: 96 out of 2680

612 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
43% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

3% of this provider’s 612 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 8,068 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

35% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$97 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
PRAVASTATIN SODIUM 340 302 1 16
SIMVASTATIN 333 294 2 1
METOPROLOL SUCCINATE 319 295 3 11
METFORMIN HCL 179 165 4 6
AMLODIPINE BESYLATE 179 169 4 3
LISINOPRIL 177 153 6 5
LEVOTHYROXINE SODIUM 175 172 7 4
ATORVASTATIN CALCIUM 171 161 8 10
FUROSEMIDE 164 161 9 7
CRESTOR 161 127 10 15
LISINOPRIL-HYDROCHLOROTHIAZIDE 149 136 11 31
OMEPRAZOLE 147 129 12 2
PANTOPRAZOLE SODIUM 141 123 13 44
WARFARIN SODIUM 131 119 14 12
ZOLPIDEM TARTRATE 112 96 15 17
CARVEDILOL 105 102 16 27
SINGULAIR 105 96 16 64
SPIRIVA 96 84 18 36
PLAVIX 94 84 19 41
NEXIUM 93 83 20 19
DONEPEZIL HCL 91 91 21 28
GABAPENTIN 90 72 22 21
LOSARTAN-HYDROCHLOROTHIAZIDE 89 89 23 46
ALENDRONATE SODIUM 88 81 24 20
CEFUROXIME 81 74 25 241
RAMIPRIL 80 77 26 49
NAMENDA 77 77 27 43
LOSARTAN POTASSIUM 75 73 28 18
CLOPIDOGREL 75 63 28 30
TIZANIDINE HCL 75 69 28 282
MELOXICAM 74 73 31 50
ATENOLOL 73 68 32 14
TAMSULOSIN HCL 70 58 33 25
CELEBREX 67 65 34 75
TRAMADOL HCL-ACETAMINOPHEN 66 62 35 167
BETAMETHASONE DIPROPIONATE 64 54 36 258
CLOTRIMAZOLE-BETAMETHASONE 64 57 36 109
ADVAIR DISKUS 63 59 38 32
SERTRALINE HCL 63 58 38 23
ALLOPURINOL 63 63 38 42
PROAIR HFA 61 51 41 52
FINASTERIDE 61 61 41 80
METOPROLOL TARTRATE 59 51 43 8
BENICAR HCT 59 59 43 125
DIOVAN HCT 59 59 43 54
PAROXETINE HCL 58 45 46 62
HYDROCHLOROTHIAZIDE 56 53 47 9
METFORMIN HCL ER 55 48 48 53
AMLODIPINE BESYLATE-BENAZEPRIL 54 53 49 58
SYNTHROID 54 47 49 39
LOVASTATIN 53 51 51 37
CYMBALTA 52 51 52 56
ATELVIA 52 50 52 164
MONTELUKAST SODIUM 52 49 52 134
CIPROFLOXACIN HCL 51 48 55 85
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 6, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.